Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients with an elective surgery or procedure. Substudy of the RE-LY trial.
In conclusion, in patients who interrupted dabigatran or warfarin for a surgery/procedure in the RE-LY trial, use of bridging anticoagulation appeared to increase the risk for major bleeding irrespective of dabigatran or warfarin interruption.
PMID: 25472710 [PubMed - as supplied by publisher]
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Douketis JD, Healey JS, Brueckmann M, Eikelboom JW, Ezekowitz MD, Fraessdorf M, Noack H, Oldgren J, Reilly P, Spyropoulos AC, Wallentin L, Connolly SJ Tags: Thromb Haemost Source Type: research
More News: Atrial Fibrillation | Bleeding | Coumadin | Databases & Libraries | Hematology | Pradaxa | Stroke | Thrombosis | Warfarin